FDA Pilot Program Accelerates Path for Generative AI Medical Devices

The FDA has introduced a pilot program, TEMPO, allowing certain generative AI medical devices to reach patients without prior marketing authorization. This initiative helps regulators gain real-world experience with cutting-edge AI technologies and provides a quicker route for digital health companies to launch their products.